RTW Biotech Opp. - Amani closes $25 million Series A financing

RTW Biotech Opportunities

31/03/2026 07:00

RNS Number : 7051Y

RTW Biotech Opportunities Ltd

31 March 2026

 

LEI: 549300Q7EXQQH6KF7Z84

31 March 2026

RTW Biotech Opportunities Ltd

Amani closes $25 million Series A financing

·      RTW new company creation, with proceeds to advance lead program AM-01 for schizophrenia

·      In-licensed worldwide rights to Phase 3-ready component of AM-01

·      RTW Bio's investment represents 0.8% of NAV as at 28 February 2026

RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to the note the announcement by private portfolio company Amani Therapeutics ("Amani") of the completion of a $25 million Series A financing.  

Amani is a biotechnology company focused on developing highly efficacious and safer medicines for people living with serious neuropsychiatric disorders. RTW Bio invested $6.6 million in the Series A financing (in addition to $0.4 million invested in a previous SAFE funding that later converted to Series A shares), the total investment representing 0.8% of NAV as of 28 February 2026. Amani is the sixth new company creation of RTW Investments, LP.

Proceeds from the financing are expected to support the advancement of AM-01, a product comprising clozapine and an in-licensed Phase 3-ready component. AM-01 is designed to potentially deliver the efficacy of clozapine while addressing its most significant safety liability, severe neutropenia, a condition characterized by low levels of a type of neutrophils (white blood cells) in the blood. Clozapine is the only therapy proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. However, its use remains limited due to safety concerns and the requirement for regular blood monitoring.

 

Rod Wong, CIO of RTW Investments, said, "We are pleased to support Amani Therapeutics in its mission to advance innovative treatments for neuropsychiatric disorders. The development of AM-01 represents a meaningful step forward towards addressing the significant unmet need in schizophrenia, and we believe Amani's approach has the potential to transform the standard of care."

 

Amani's announcement can be found here.

 

Enquiries:

RTW Investments, LP - Investment Manager
Oliver Kenyon
Krisha McCune (Investor Relations)
+44 (0)20 7959 6362
biotechopportunities@rtwfunds.com
Cadarn Capital - PR & IR Partner
Lucy Clark (PR)
David Harris (Distribution)
+44 (0)7984 184 461 / lucy@cadarncapital.com
+44 (0)7368 883 211 /david@cadarncapital.com
Deutsche Numis - Joint Corporate Broker
Nathan Brown
Duncan Monteith
George Shiel
+44 (0)20 7260 1000
BofA Securities - Joint Corporate Broker
Edward Peel
Alex Penney
+44 (0)20 7628 1000
Altum (Guernsey) Limited
Joanna Duquemin Nicolle
Sadie Morrison
+44 (0)1481 703 100

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com for more information.

 

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
PFUEAXDEDFKKEFA